Peter Zeihan: Europe Goes Nuclear
We’ve got two major developments in Eurasia. We’re talking about Ukraine disabling two ships in the Caspian Sea and Poland getting EU approval to build…
Thought Leader: Peter Zeihan
How Obama’s FDA Keeps Generic Drugs Off the Market
August 19, 2016
Source: Link
By Dr. Scott Gottlieb (original source The Wall Street Journal)
“One of the biggest factors fueling the angst over drug prices in the U.S. is that some older medicines that should be sold cheaply as generics are still priced very high, often owing to a dwindling number of generic competitors and the rising cost of producing these drugs.Bernie Sanders and Hillary Clinton like to blame generic-company mergers and greedy drugmakers. But a closer look reveals that a series of regulatory policy blunders is at fault.
The modern generic-drug industry emerged after the 1984 Drug Price Competition and Patent Term Restoration Act, better known as Hatch-Waxman. The law created a cheaper and faster path for bringing generic copies of branded drugs to the market. By keeping regulatory barriers low, Hatch-Waxman enabled vigorous competition from multiple firms, each one vying to sell drugs for close to the cost of manufacturing.”
Click here to read more
Relevant and recent posts
Dr. Sanjay Gupta’s Top Health Stories of 2025
From the resurgence of measles to a new way to treat pain, 2025 was a challenge for public health while still offering moments of hope. Sanjay…
Thought Leader: Sanjay Gupta
Ian Bremmer: The state of global conflict in 2025
On GZERO World, Ian Bremmer takes a hard look at the biggest global crises and conflicts that defined our world in 2025 with CNN’s Clarissa…
Thought Leader: Ian Bremmer
Recent posts
Peter Zeihan: Europe Goes Nuclear
Thought Leader: Peter Zeihan
Dr. Sanjay Gupta’s Top Health Stories of 2025
Thought Leader: Sanjay Gupta
Ian Bremmer: The state of global conflict in 2025
Thought Leader: Ian Bremmer